- Home
- SRZN vs SAVA Comparison
SRZN vs SAVA Comparison
Compare SRZN & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- SAVA
- Stock Information
- Founded
- SRZN 2015
- SAVA 1998
- Country
- SRZN United States
- SAVA United States
- Employees
- SRZN N/A
- SAVA N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- SAVA Health Care
- Exchange
- SRZN Nasdaq
- SAVA Nasdaq
- Market Cap
- SRZN 82.8M
- SAVA 70.5M
- IPO Year
- SRZN N/A
- SAVA N/A
- Fundamental
- Price
- SRZN $7.10
- SAVA $2.09
- Analyst Decision
- SRZN Strong Buy
- SAVA Buy
- Analyst Count
- SRZN 2
- SAVA 3
- Target Price
- SRZN $38.50
- SAVA $54.50
- AVG Volume (30 Days)
- SRZN 11.0K
- SAVA 989.7K
- Earning Date
- SRZN 05-09-2025
- SAVA 05-08-2025
- Dividend Yield
- SRZN N/A
- SAVA N/A
- EPS Growth
- SRZN N/A
- SAVA N/A
- EPS
- SRZN N/A
- SAVA N/A
- Revenue
- SRZN $11,638,000.00
- SAVA N/A
- Revenue This Year
- SRZN N/A
- SAVA N/A
- Revenue Next Year
- SRZN N/A
- SAVA N/A
- P/E Ratio
- SRZN N/A
- SAVA N/A
- Revenue Growth
- SRZN N/A
- SAVA N/A
- 52 Week Low
- SRZN $6.00
- SAVA $1.15
- 52 Week High
- SRZN $18.17
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- SRZN 31.40
- SAVA 69.61
- Support Level
- SRZN $9.96
- SAVA $1.78
- Resistance Level
- SRZN $11.56
- SAVA $1.67
- Average True Range (ATR)
- SRZN 0.96
- SAVA 0.13
- MACD
- SRZN -0.29
- SAVA 0.07
- Stochastic Oscillator
- SRZN 21.20
- SAVA 73.99
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.